Search Results

Crescendo Biologics Ltd, a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024.

Crescendo Biologics Ltd has presented preclinical data at the 2024 American Association for Cancer Research Annual Meeting on its two leading programmes.

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that the first patients in the U.S. have been dosed as part of the ongoing Phase 1b study of CB307, Crescendo’s lead programme in PSMA+ metastatic castration-resistant prostate cancer (mCRPC).

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that it has signed a contract with a new customer, Crescendo Biologics Limited.

Crescendo Biologics Ltd today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.

Axsome Therapeutics, Inc. today announced topline results from the CRESCENDO (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy) survey of patients with narcolepsy type 1 (NT1, i.e., narcolepsy with cataplexy) receiving treatment, demonstrating high rates of persistent symptoms and significant patient burden, despite being on current treatments.

This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.

WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.

Biologics Market Outlook 2024-2032: